Loading company
Genmab A/S
GMAB · Nasdaq · Healthcare · Biotechnology
Next earnings: November 5, 2026 · before the open
$35.32+1.4%Sep 25 close
- 1M
- +6.3%
- 6M
- +36.8%
- 1Y
- +21.5%
- 5Y
- -21.3%
GMAB · Nasdaq · Healthcare · Biotechnology
Next earnings: November 5, 2026 · before the open
$35.32+1.4%Sep 25 close
Three ratings, each a percentile against the 585 companies we cover in Biotechnology. Deliberately kept apart rather than blended into one score — cheap, rising and well-run are three different facts, and a single number would hide which one is which.
Above most of its industry
The most recent month is left out on purpose: returns tend to persist over 7–12 months and the newest one tends to reverse. This describes what the price has done, and says nothing about what it will do.
Near the top of its industry
Yields, so higher means cheaper — a loss-making company ranks last instead of dropping out. Cheap is not the same as good: a high yield is often a price that fell for a reason. All five measures available.
1 check not reported
What management does with the money — scored on whatever the filings answer, never as a share of the total.
A description of where this company sits among its competitors, not a recommendation. Ratings updated Sep 26, 2026.
Built from Genmab A/S’s own filings with the SEC. Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
Is the business getting bigger, and does it generate real cash?
Showing 2 of 11 quarters of Genmab A/S’s grade history. The other 9 go back to March 2020.